Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Vicki Kelemen Biography and Net Worth

COO of Cardiff Oncology

Vicki Kelemen has served as Chief Operating Officer since 2020, and previously as Vice President of Clinical Development and Investor Relations since 2018, and Vice President of Corporate Communications from 2017 to 2018 and Senior Director of Marketing Communications from 2015 to 2017.

Prior to joining Cardiff Oncology (formerly Trovagene), Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive operations, marketing and communications management and executive positions and lead the development and launch of several novel products with pharma/biotech companies focused in therapeutics, including Amylin, Maxim, Agouron (Pfizer), Valeant, Ardea Biosciences (Astra Zeneca) and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.

Ms. Kelemen has a BS degree in pre-med and medical anthropology from the University of California at Davis.

What is Vicki Kelemen's net worth?: The estimated net worth of Vicki Kelemen is at least $15,132.50 as of March 23rd, 2021. Ms. Kelemen owns 6,053 shares of Cardiff Oncology stock worth more than $15,133 as of November 21st. This net worth evaluation does not reflect any other assets that Ms. Kelemen may own. Learn More about Vicki Kelemen's net worth.
How do I contact Vicki Kelemen?: The corporate mailing address for Ms. Kelemen and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on Vicki Kelemen's contact information.
Has Vicki Kelemen been buying or selling shares of Cardiff Oncology?: Vicki Kelemen has not been actively trading shares of Cardiff Oncology over the course of the past ninety days. Most recently, on Tuesday, March 23rd, Vicki Kelemen bought 960 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $10.31 per share, with a total value of $9,897.60. Following the completion of the transaction, the chief operating officer now directly owns 6,053 shares of the company's stock, valued at $62,406.43. Learn More on Vicki Kelemen's trading history.
Who are Cardiff Oncology's active insiders?: Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.
Are insiders buying or selling shares of Cardiff Oncology?: In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $41,100.00. The most recent insider tranaction occured on December, 19th when Director Gary W Pace bought 30,000 shares worth more than $41,100.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.
Information on this page was last updated on 12/19/2023.

Vicki Kelemen Insider Trading History at Cardiff Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/23/2021	Buy	960	$10.31	$9,897.60	6,053

Vicki Kelemen Buying and Selling Activity at Cardiff Oncology

Cardiff Oncology Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $2.50

$2.46

$2.59

50 Day Range

MA: $2.84

$2.46

$4.09

2 Week Range

Now: $2.50

$1.13

$6.42

Volume

459,915 shs

Average Volume

945,558 shs

Market Capitalization

$127.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Get Your Free Gold Guide